Biogen's drug for cutaneous lupus erythematosus shows promising results in reducing disease activity, marking a significant advancement in their immunology and inflammation pipeline. Analysts view this as a crucial derisking step for the company's future prospects.
William Blair hailed a positive readout in cutaneous lupus erythematosus as a turning point for Biogen, while RBC Capital analysts called the results “another derisking step” for the company’s immunology and inflammation pipeline.
Original title: “Biogen's Lupus Drug Reduces Disease Activity, Further Deresking I&I Pipeline”